New Animal Models for Encapsulating Peritoneal Sclerosis

Abstract

Objective

Encapsulating peritoneal sclerosis (EPS), in which all or part of the intestine is enveloped in a fibrous ball resembling a cocoon, is a serious complication of peritoneal dialysis (PD). The aim of the present study was to investigate whether pH-neutral or acidic dialysis solutions induce peritoneal fibrosis.

Design

We divided 18 male Wistar–Kyoto (WKY) rats into three groups and dialyzed them with various solutions as follows: group I, 10 mL acidic dialysis solution (pH 3.8, containing 1.35% glucose), n = 6; group II, 10 mL pH 5.0 dialysis solution, n = 6; and group III, 10 mL neutral dialysis solution (pH 7.0), n = 6. Peritoneal catheters were inserted, and dialysis solution was injected every day for 40 days. At the end of the experiment, a peritoneal equilibration test (PET) was performed. Expression of mRNA of aquaporins 1 and 4 (AQP-1 and AQP-4) in the peritoneum were studied by semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR).

Results

In rats treated with pH 3.8 dialysis solution, necropsy findings revealed features identical to those of EPS. The typical appearance was of granulation tissue or fibrotic tissue (or both) covering multiple surfaces. Multiple adhesions were present. In microscopic examinations, peritoneal fibrosis and loss of mesothelium were found. In rats treated with pH 7.0 dialysis solution, no signs of EPS were seen. In rats treated with pH 5.0 dialysis solution, milder changes (subserosal thickening and partial adhesion of the peritonea) were observed. The mRNA of AQP-1 and AQP-4 were expressed in the peritonea of the rats. The expression of the AQPs was significantly suppressed in rats treated with pH 3.8 dialysis solution.

Conclusions

In rats, long-term intraperitoneal injection of acidic dialysis solution produced features typical of EPS in humans. Newly developed neutral dialysis solutions protected the against the development of EPS during peritoneal dialysis in rats.

Keywords

Encapsulating peritoneal sclerosis (EPS)neutral fluid continuous ambulatory peritoneal dialysis fibrosis

Get full access to this article

View all access options for this article.

References

Shao

J.C.

, Yorioka

, Nishida

, Yamakido

Effect of pH and glucose on cultured human peritoneal mesothelial cells.

Scand J Urol Nephrol 1999; 33: 248–56.

Gandhi

V.C.

, Humayun

H.M.

, Ing

T.S.

, Daugirdas

J.T.

, Geis

W P.

, Hano

J.E.

Sclerosing thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.

Arch Intern Med 1980; 140: 1201–3.

Nomoto

, Kawaguchi

, Kubo

, Hirano

, Sakai

, Kurokawa

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.

Am J Kidney Dis 1996; 28: 420–7.

Slingeneyer

, Mion

, Mourad

, Canaud

, Faller

, Beraud

J.J.

Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis.

Trans Am Soc Artif Intern Organs 1983; 29: 633–40.

Rottembourg

, Issad

, Langlois

, Tranbaloc

, Adamou

, DeGroc

Loss of ultrafiltration and sclerosing encapsulating peritonitis during CAPD evaluation of the potential risk factors.

Adv Perit Dial 1985; 1: 109–17.

Slingeneyer

Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis.

Contrib Nephrol 1987; 57: 239–47.

Wieczorowska

, Khanna

, Moore

H.L.

, Nolph

K.D.A.

, Twardowski

Z.J.

Rat model of peritoneal fibrosis: preliminary observation.

Adv Perit Dial 1995; 11: 48–50.

U.S. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Bethesda: National Institutes of Health; 1985.

Imai

, Nakamoto

, Ishida

, Inoue

, Kanno

, Okada

Glucocorticoid restores the deterioration of water transport in the peritoneum through increment in aquaporin.

Adv Perit Dial 2000; 16: 297–302.

10.

Jörres

, Gahl

G.M.

, Topley

, Neubauer

, Ludat

, Muller

In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions.

Nephrol Dial Transplant 1994; 9: 785–90.

11.

Rooney

O.B.

, Dodd

P.D.

, Gokal

, Walker

M.G.

Dialysis fluid cytotoxicity and inhibition of host defense in cultured human mesothelial cells are neutralized rapidly with incubation in the peritoneum.

Nephrol Dial Transplant 1996; 11: 2472–7.

12.

Rippe

, Simonsen

, Heimbürger

, Christensson

, Haraldsson

, Stelin

Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.

Kidney Int 2001; 59: 348–57.

New Animal Models for Encapsulating Peritoneal Sclerosis—Role of Acidic Solution